Royalty origination across life sciences
We use our own AI models to find royalties and introduce their holders to asset managers and royalty funds, who may buy the royalties or lend against them. Holders may use the money as they choose.
Medtech, animal health, and crops and seeds; sales for the latest year available. Sources: IQVIA, Kalorama, AgbioInvestor, HealthforAnimals, Gibson Dunn Royalty Finance Tracker; classification by Capital for Cures. See the data
What we do
A royalty is a share of sales paid for the use of an invention: a 5% royalty on a product selling $200m a year pays the holder $10m a year. Royalty financing turns those future payments into money today.
See five worked examples, deal options and royalty terms in plain words on the For royalty holders page.
A financing tool that has barely left pharma
Wherever technology is licensed, royalties are paid: on drugs and vaccines, medical devices, animal medicines, software, and plant varieties and traits. In pharma, holders regularly sell these royalties or borrow against them. In the other areas the instrument works the same way, but few deals are made public. We bring royalties from all six areas to asset managers and royalty funds, and we are working to grow royalty financing across life sciences.
| Area | What is licensed | How the royalty is paid | Financings, 2020 to 2025 | Market |
|---|---|---|---|---|
| Pharma | A drug, licensed to a partner that sells it | A percentage of net sales | 127 | Established market |
| Vaccines | An antigen, an adjuvant or a vaccine platform | A percentage of sales, or a fee per dose | 1 | Rare |
| Medtech | A device design or a component technology | A percentage of device sales | 2 | Rare |
| Animal health | A medicine or vaccine for pets or livestock | A percentage of sales | 1 | Rare |
| Digital health | Software, an algorithm or a data set | A share of licence or subscription revenue | 0 | No listed deals |
| Crops and seeds | A plant variety or a genetic trait | A fee per unit of seed sold, or a share of sales | 0 | No listed deals |
For asset managers and royalty funds
We find royalties in all six areas, prepare the information you need to review them and bundle smaller ones into portfolios. How we work with investors
Our weekly analysis of royalty deals
Read by more than 500 royalty investors, lawyers and dealmakers.
17 November 2026 Royalties past the patent: Kimble in the United States and the new technology transfer rules in Europe
16 November 2026 The rate that does not reset: royalty finance after cheap money
15 November 2026 The Weekly Term Sheet (2026-W46)
14 November 2026 The Gulf licence: what royalty from the Middle East might be worth